Open AccessAn Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines
Author(s) -
Joel L. Cohen,
Joel Schlessinger,
Sue Ellen Cox,
Xiaoming Lin
Publication year - 2009
Publication title -
aesthetic surgery journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.528
H-Index - 58
eISSN - 1527-330X
pISSN - 1090-820X
DOI - 10.1016/j.asj.2009.09.003
Subject(s) - medicine , dosing , adverse effect , incidence (geometry) , gastroenterology , surgery , optics , physics
A new formulation of botulinum neurotoxin type A (BoNTA-ABO; Dysport [abobotulinumtoxinA]; Medicis Aesthetics, Scottsdale, AZ) was recently approved by the US Food and Drug Administration for the treatment of moderate to severe glabellar lines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom